Results 61 to 70 of about 757 (146)

Pharmacokinetics and Safety of Single and Multiple Doses of Molnupiravir in Healthy Male Chinese Adults: An Open‐Label, Fixed Sequence, Phase 1 Study

Clinical and Translational Science, Volume 19, Issue 4, April 2026.
ABSTRACT Molnupiravir is an orally administered prodrug of β‐D‐N4‐hydroxycytidine (NHC) that is conditionally approved in China for the treatment of mild to moderate COVID‐19 in nonhospitalized adults at high risk of disease progression. Molnupiravir is rapidly absorbed and hydrolyzed to deliver NHC into systemic circulation.
Jixiang Zhu, Danning Zhang, Zhiping Liu, Bei Yan, Yanqiao Zang, Weiwei Zhao, Fang Sun, Brian M. Maas, Mickie H. Cheng, S. Aubrey Stoch, Haiyan Li   +10 more
wiley   +1 more source

Are Tetrapleura tetraptera Phytochemicals Druggable Against SARS‐CoV‐2 Papain‐Like Protein? A Computational Approach

New Zealand Journal of Botany, Volume 64, Issue 1, March 2026.
SARS‐CoV2 Omicron and its substrains are still a critical global health issue and extremely contagious, even with widespread vaccination efforts. Hospitalizations and mortality rates linked to these variants are still prevalent. Current therapeutic options face challenges, including low effectiveness, suboptimal pharmacokinetics, and drug resistance ...
Frank Eric Tatsing Foka, Hazel Tumelo Mufhandu   +1 more
wiley   +1 more source

Characteristics of patients with non-severe infections of different SARS-CoV-2 omicron subvariants in China. [PDF]

Front Med (Lausanne)
ObjectiveThe aim of this study was to explore the clinical characteristics of patients infected with different Omicron subvariants presenting non-severe disease, evaluate the safety and efficacy of Azvudine for treatment of COVID-19, in order to broaden ...
Yuan W, Liu Y, Zhan H, Wei F, Zhang Q, Gao H, Yan H, Huang T, Li Y, Dai E.   +9 more
europepmc   +2 more sources

Disruption of Spike Priming in Virus Entry: Tetrandrine as a Pan‐Coronavirus Inhibitor

MedComm, Volume 6, Issue 9, September 2025.
Tetrandrine inhibits the infection of HCoV‐OC43, HCoV‐229E, SARS‐CoV‐2, and its major variants by blocking virus entry. Specifically, tetrandrine breaks the interaction between TMPRSS2 and Spike, therefore suppress its priming and the following membrane fusion, and induces Spike to degradation.
Kun Wang, Huiqiang Wang, Shuo Wu, Ge Yang, Haiyan Yan, Lijun Qiao, Xingqiong Li, Mengyuan Wu, Jiandong Jiang, Yuhuan Li   +9 more
wiley   +1 more source

Effectiveness and safety of azvudine versus nirmatrelvir-ritonavir in adult patients infected with COVID-19 omicron strains: a retrospective study in Beijing. [PDF]

Sci Rep
The study was to evaluate the clinical outcomes of azvudine versus nirmatrelvir-ritonavir against omicron strains of coronavirus disease 2019 infections and determine their comparative effectiveness.
Xie H, Wang Y, Xu Y, Wang L, Fan J, Pan S, Shi C, Liu X, Gao X, Guo X, Yu S, Liu J, Zhang D, Yang Y, Zhang H, Wang J, Wu A, Liu X, Liu J, Zhu H, Zhou X, Tian X, Wang M.   +22 more
europepmc   +2 more sources

Clinical Characteristics and Treatment Efficacy in Patients With SARS‐CoV‐2 Positivity After Nirmatrelvir‐Ritonavir Therapy

Journal of Medical Virology, Volume 97, Issue 5, May 2025.
ABSTRACT Nirmatrelvir‐ritonavir (NMV‐r) has been widely used to treat coronavirus disease 2019 (COVID‐19) for a standard period of 5‐days. However, there are increasing reports of patients with persistent severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) positivity after the standard 5‐day course of NMV‐r treatment.
Huqin Yang, Leyi Gao, Yi Xue, Zhijin Zhang, Lujia Guan, Haifan Zhang, Haomiao Ma, Xuyan Li, Jieqiong Li, Zhaohui Tong   +9 more
wiley   +1 more source

Evaluation of oral small molecule drugs for the treatment of COVID-19 patients: a systematic review and network meta-analysis

, 2023
At present, there are some randomized controlled trials (RCTs) of oral small molecule drugs. The purpose of this study was to evaluate the efficacy and safety of oral small molecule drug treatment for COVID-19.
Fangyuan Tian (1570417), Zhaoyan Chen (461261)   +1 more
core   +2 more sources

Clinical Characteristics of SARS‐COV‐2 Omicron Variant in Acute Myeloid Leukemia and Acute Lymphocytic Leukemia Patients: A Multi‐Center Retrospective Study

Cancer Reports, Volume 8, Issue 4, April 2025.
ABSTRACT Background The death rate of hematological malignancies is high, and the death rate of patients with COVID‐19 infection is further increased. Although there have been expert consensus and relevant guidelines to introduce the recommendations of the guidelines for patients with hematological malignancies complicated with COVID‐19 infection ...
Lin Wang, Ruihua Mi, Lin Chen, Jia Liu, Haiping Yang, Meng Hu, Zhao Xiaoqiang, Yan Zhang, Xiaobing Xu, Bing Liu, Hongmian Zhao, Li Qianyu, Tao Liu, Chen Zhenzhu, Jinxiao Yao, Ying Yang, Xudong Wei   +16 more
wiley   +1 more source

Effectiveness and Safety of Simnotrelvir/Ritonavir and Nirmatrelvir/Ritonavir in the Treatment of Moderate to Severe COVID‐19

Immunity, Inflammation and Disease, Volume 13, Issue 4, April 2025.
This is the first study comparing the effectiveness of simnotrelvir/ritonavir and nirmatrelvir/ritonavir in treating moderate and severe COVID‐19 patients. Patients who received simnotrelvir/ritonavir exhibited shorter hospitalization. Disease progression, viral clearance times, and symptom resolution time were similar between the two groups.
Xin Chen, Xiao‐Qing Lin, Fang Cheng, Shi‐Lin Zheng, Qiang Zhang, Te Wu, Xian‐Gao Jiang, Ji‐Chan Shi   +7 more
wiley   +1 more source

Composite Interventions on Outcomes of Severely and Critically Ill Patients with COVID-19 in Shanghai, China

, 2023
Background: The sixty-day effects of initial composite interventions for the treatment of severely and critically ill patients with COVID-19 are not fully assessed.
Chengnan Guo, Fengdi Zhang, Jianrong Hu, Liou Cao, Runsheng Guo, Gang Huang, Xuyuan Huang, Jiasheng Shao, Rong Fan   +8 more
core   +1 more source